Heartseed
Tokyo, JapanWebsite
A clinical-stage biotechnology company focused on the development of cardiac regenerative medicine therapies using human iPSC-derived cardiomyocytes.
Loading company information...
A clinical-stage biotechnology company focused on the development of cardiac regenerative medicine therapies using human iPSC-derived cardiomyocytes.
Company context
Heartseed prompts can include culture, product, and business context from this profile.
Role targeting
Pair this profile with an open role to generate focused behavioral and technical questions.
Answer coaching
Practice responses, get feedback, and refine stories before applying or interviewing.
Heartseed is a clinical-stage biotechnology company based in Tokyo, Japan, at the forefront of cardiac regenerative medicine. Founded in 2015 by Dr. Keiichi Fukuda, a pioneer in stem cell research, the company focuses on developing innovative therapies for heart failure. By utilizing induced pluripotent stem cell (iPSC)-derived cardiomyocytes, Heartseed aims to achieve 'remuscularization'—the regeneration of damaged heart muscle tissue—to provide a curative alternative to traditional heart transplants.
Heartseed's mission is to provide curative therapy for heart failure patients worldwide, aiming to make cardiac regenerative medicine a common, accessible treatment that overcomes the limitations of donor scarcity and invasive surgery.
Founded
2015
Headquarters
Shinjuku-ku, Tokyo, Japan
Employees
50-200
Industry
Biotechnology
Opportunity to work on groundbreaking, world-first medical technologies
Strong backing from major global pharmaceutical partners like Novo Nordisk
High-pressure environment typical of clinical-stage biotech startups
Long development timelines inherent to regenerative medicine clinical trials
Funding
Publicly traded (TSE Growth Market)
CEO
Keiichi Fukuda